Summary of BNB Plus Conference Call Company Overview - **Company**: BNB Plus - **Key Executives**: Patrick Horsman (Chief Investment Officer), Joshua Kruger (Chairman of the Board) - **Background**: BNB Plus focuses on digital asset treasury (DAT) strategies, particularly leveraging the BNB ecosystem, which is associated with Binance, the largest cryptocurrency exchange globally. Industry Insights - **Industry**: Cryptocurrency and Digital Assets - **Market Position**: Binance has over 300 million users globally, with $145 trillion traded since its inception in 2017, and $34 trillion traded in 2025 alone [7][18] - **Competitive Landscape**: Binance accounts for 40% of global liquid trading on centralized exchanges, significantly outperforming competitors like Coinbase, which holds only 6% [21] Core Strategies and Financial Insights - **Yield Generation**: BNB Plus employs four non-directional yield strategies targeting an annualized return of 9%-12% [10][18] 1. **Native Staking**: Provides a base yield of approximately 2% [13] 2. **Launchpool Airdrops**: Historically yielded 9%-14% annualized returns from airdropped tokens [9][15] 3. **Liquidity Provisioning**: Engaging in automated market-making strategies, yielding around 7%-9% [15][16] 4. **Collateralization**: Borrowing stablecoins against BNB for low-risk yield strategies [16] - **Tokenomics of BNB**: BNB has a deflationary model with a quarterly burn mechanism, reducing the supply and increasing the value for holders. Over the last 12 months, over $1 billion worth of tokens were burned each quarter [19][20] Risk Management - **Non-Directional Strategies**: The strategies are designed to minimize risk while generating yield, focusing on productive assets like BNB rather than speculative investments [10][35] - **Market Volatility**: BNB Plus aims to protect shareholder value during market downturns by continuing to generate yield and compounding BNB holdings without selling during dips [35][36] Future Outlook - **U.S. Market Entry**: There is potential for Binance to enter the U.S. market, which could significantly boost business operations [21][42] - **Growth Projections**: BNB Plus aims to grow its balance sheet significantly, targeting hundreds of millions in BNB holdings over time [28] Conclusion - **Investment Proposition**: BNB Plus offers a unique opportunity to gain exposure to Binance and the BNB ecosystem, which is viewed as a productive asset with significant growth potential. The company positions itself as a way to access the value of Binance without direct public investment opportunities [22][43]

BNB Plus (NasdaqCM:APDN) Conference January 27, 2026 01:00 PM ET Company ParticipantsJosh Kruger - Chair of the BoardPatrick Horsman - Chief Investment OfficerModeratorOn behalf of Virtual Investor Conferences, we are very pleased you've joined us for our Digital Asset Conference. Our last presentation of the day is from BNB Plus. Please note you may submit questions for the presenter in the box to the left of the slides. You can also view a company's availability for one-on-one meetings by clicking Book a ...

As filed with the Securities and Exchange Commission on December 22, 2025. Registration Statement No. 333-291156 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 BNB Plus Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 50 Health Sciences Drive Stony Brook, New York 11790 631-240-8800 (Address, including zip code, and telephone ...

Table of Contents As filed with the Securities and Exchange Commission on October 29, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Applied DNA Sciences, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) 50 Health Sciences Drive Stony Brook, New York 11 ...

吴说获悉，生物技术公司 Applied DNA Sciences (NASDAQ: APDN) 宣布获得最高 5800 万美元 PIPE 投 资承诺，以启动基于 BNB 的数字资产财务战略。目前已获 2700 万美元认购（含现金、稳定币及 OBNB 信托单位），并可通过认股权证再筹资最高 3100 万美元，交易预计于 2025 年 10 月 1 日完成。 公司已与 Cypress LLC 签署五年期战略服务协议，由其提供 BNB 储备的全权管理。 （来源：吴说） 来源：市场资讯 ...

[Business Transition and Strategy](index=1&type=section&id=Business%20Transition%20and%20Strategy) Applied DNA transitioned to a pure-play synthetic DNA and mRNA solutions provider, focusing on LineaDNA™, LineaRNAP™, and LineaIVT™ - The company has transitioned to a pure-play provider of synthetic DNA and mRNA manufacturing solutions for advanced biotherapeutics and diagnostics[3](index=3&type=chunk) - Commercialization efforts focus on LineaDNA™ (cell-free DNA production), LineaRNAP™ (next-gen T7 RNA polymerase), and LineaIVT™ (an integrated system combining both)[3](index=3&type=chunk) [Management Commentary](index=2&type=section&id=Management%20Commentary) Management confirms operations align with core cell-free DNA and mRNA manufacturing, focusing on shareholder value - Management confirms the company is repositioned as a single business focused on its core competencies in cell-free DNA and mRNA manufacturing solutions[4](index=4&type=chunk) - The company is actively marketing its offerings under the LineaRx brand to deliver value to shareholders[4](index=4&type=chunk) [Recent Corporate and Operational Updates](index=2&type=section&id=Recent%20Corporate%20and%20Operational%20Updates) The company achieved significant operational progress, including reduced cash burn and key commercial milestones - Monthly net cash burn from operations declined approximately **19% sequentially** and **25% year-over-year** due to cost-cutting initiatives[5](index=5&type=chunk) - Received a multi-gram follow-on order for LineaDNA valued at over **$600 thousand** from a global manufacturer of IVDs for a cancer diagnostic application[8](index=8&type=chunk) - Acquired a U.S.-based mRNA contract development manufacturing organization (CDMO) as a new customer for LineaDNA IVT templates[8](index=8&type=chunk) - Launched the LineaRx IVT Discovery Kit to facilitate customer evaluation and initiated industry marketing for LineaRNAP as a standalone product[8](index=8&type=chunk) - Initiated ISO 13485 certification, an international quality management standard, with expected completion in the first quarter of fiscal 2026[13](index=13&type=chunk) [Third Quarter Fiscal 2025 Financial Highlights](index=3&type=section&id=Third%20Quarter%20Fiscal%202025%20Financial%20Highlights) Q3 FY2025 highlights include **$304 thousand** revenue, **$3.7 million** operating loss, and **$4.7 million** cash Q3 FY2025 Key Financial Metrics (vs. Q3 FY2024) | Metric | Q3 FY2025 ($) | Q3 FY2024 ($) | | :--- | :--- | :--- | | Total Revenues | $304 thousand | $473 thousand | | Operating Loss | $3.7 million | $3.3 million | | Adjusted EBITDA | ($3.9 million) | ($3.2 million) | Cash Position and Burn Rate | Metric | Amount ($) | | :--- | :--- | | Cash and Cash Equivalents (as of June 30, 2025) | $4.7 million | | Monthly Net Cash Burn (Q3 FY2025) | $934 thousand | - The company executed two reverse stock splits: a **1-for-50** effective March 14, 2025, and a **1-for-15** effective June 2, 2025[11](index=11&type=chunk) - Financial results have been recast to report the closed MDx Testing Services business as discontinued operations, with the DNA Tagging segment wind-down included in continuing operations[9](index=9&type=chunk)[10](index=10&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) This section presents unaudited condensed consolidated financial statements and Adjusted EBITDA reconciliation [Condensed Consolidated Balance Sheets](index=6&type=section&id=CONDENSED%20CONSOLIDATED%20BALANCE%20SHEETS) As of June 30, 2025, total assets were **$9.9 million**, cash **$4.7 million**, and liabilities **$2.9 million** Balance Sheet Summary (as of June 30, 2025) | Account | June 30, 2025 ($) | September 30, 2024 ($) | | :--- | :--- | :--- | | Cash and cash equivalents | $4,727,677 | $5,852,363 | | Total current assets | $5,628,902 | $8,047,671 | | Total assets | $9,934,746 | $12,789,040 | | Total current liabilities | $2,035,960 | $2,398,124 | | Total liabilities | $2,946,702 | $3,820,955 | | Total equity | $6,988,044 | $8,968,085 | [Condensed Consolidated Statements of Operations](index=7&type=section&id=CONDENSED%20CONSOLIDATED%20STATEMENTS%20OF%20OPERATIONS) Q3 FY2025 revenues were **$304,393**, operating loss **$3.7 million**, and net loss **$19.4 million** Statement of Operations (Three Months Ended June 30) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Total Revenues | $304,393 | $472,789 | | Gross Profit | $5,130 | $242,601 | | Loss from Operations | ($3,694,060) | ($3,306,293) | | Net (Loss) Income from Continuing Operations | ($3,647,914) | $1,883,292 | | Net (Loss) Income Attributable to Common Stockholders | ($19,445,607) | $1,879,796 | | Net (Loss) Income Per Share | ($34.00) | $1,170.48 | [Reconciliation of Non-GAAP Measures (Adjusted EBITDA)](index=8&type=section&id=CALCULATION%20AND%20RECONCILIATION%20OF%20ADJUSTED%20EBITDA) Consolidated Adjusted EBITDA loss for Q3 FY2025 was **$3.9 million**, compared to **$3.2 million** prior year Adjusted EBITDA Reconciliation (Three Months Ended June 30) | Metric | 2025 ($) | 2024 ($) | | :--- | :--- | :--- | | Net (Loss) Income | ($3,984,109) | $1,849,501 | | Consolidated Adjusted EBITDA (Loss) | ($3,927,551) | ($3,175,688) |

Financial Performance - Total revenues for the three months ended June 30, 2025, were $304,393, a decrease of 35.5% compared to $472,789 for the same period in 2024[12] - Product revenues decreased to $195,262 for the three months ended June 30, 2025, down 20.9% from $246,644 in the prior year[12] - Gross profit for the nine months ended June 30, 2025, was $1,006,887, representing a 30.2% increase from $772,829 in the same period of 2024[12] - The company reported a consolidated net loss of $(3,984,109,000) for the three-month period ended June 30, 2025, compared to a net income of $1,849,501,000 in the same period of 2024[104] - For the nine-month period ended June 30, 2025, total revenues were $1,937,506,000, compared to $2,618,313,000 for the same period in 2024, reflecting a decrease of approximately 26%[103] Operating Expenses and Losses - Operating expenses for the three months ended June 30, 2025, totaled $3,699,190, an increase of 4.2% from $3,548,894 in the prior year[12] - The company reported a loss from operations of $(3,694,060) for the three months ended June 30, 2025, compared to a loss of $(3,306,293) in the same period of 2024[12] - For the nine-month period ended June 30, 2025, the company reported a net loss of $9,988,942, compared to a net loss of $3,774,563 for the same period in 2024[16] - The company incurred a net loss from continuing operations of $9,585,822 for the nine months ended June 30, 2025, compared to $3,502,166 in the prior year[16] Cash and Assets - Cash and cash equivalents decreased to $4,727,677 as of June 30, 2025, down 19.2% from $5,852,363 as of September 30, 2024[11] - Total assets decreased to $9,934,746 as of June 30, 2025, a decline of 22.2% from $12,789,040 as of September 30, 2024[11] - Total liabilities decreased to $2,946,702 as of June 30, 2025, down 22.8% from $3,820,955 as of September 30, 2024[11] Workforce and Restructuring - The company implemented a workforce reduction of approximately 27% of its headcount, resulting in a projected 31% reduction in annual payroll expenses compared to the fiscal year ended September 30, 2024[19] - The company expects to incur approximately $300,000 in one-time charges related to the workforce reduction and ceasing operations at ADCL[111] - The company completed a workforce reduction of 39% in headcount, projecting a 31% total reduction in payroll expenses compared to the fiscal year ended September 30, 2024[177] Revenue Streams and Business Segments - The company is strategically exiting its DNA Tagging and Security Products and Services segment, which may impact future revenue streams[51] - The company has exited its MDx Testing Services business effective June 27, 2025, and accounted for its operations as discontinued[19] - The company is focused on the development and commercialization of its three technology solutions: LineaDNA, LineaRNAP, and LineaIVT, aimed at addressing unmet needs in the biopharmaceutical and diagnostics industries[122] Stock and Financing Activities - The company completed a one-for-fifty reverse stock split on March 14, 2025, followed by a one-for-fifteen reverse stock split on June 2, 2025[20] - The Company completed a registered direct offering on October 31, 2024, raising approximately $5.7 million in net proceeds after fees[70] - The Company executed a reverse stock split of one-for-fifty shares on March 14, 2025, and a subsequent one-for-fifteen split on June 2, 2025[65][67] Compliance and Legal Matters - The Company received a Notification Letter from Nasdaq on November 12, 2024, indicating non-compliance with the minimum bid price requirement of $1.00 per share, which was later resolved by regaining compliance by April 7, 2025[83][84] - The Company was notified on May 30, 2025, that it no longer satisfied the Bid Price Rule, leading to a request for a hearing to avoid delisting[86][87] - The Company had no pending litigation at the time of the report, indicating a stable legal standing[100] Management Changes - Dr. James A. Hayward retired as CEO on June 18, 2025, with a separation agreement providing for a total gross payment of $450,000 over eight months[96][97] - Judith Murrah was elected as the new CEO effective June 18, 2025, and agreed to a 15% temporary reduction in her annual base salary to $340,000[98] Miscellaneous - The effect of inflation on revenue and operating results was not significant[191] - The company filed a conformed version of its Certificate of Incorporation, effective June 2, 2025[207] - Certifications of the Chief Executive Officer and Chief Financial Officer were filed pursuant to the Sarbanes-Oxley Act of 2002[207]

Revenue Performance - LineaRx segment revenues increased by 44% year-over-year, contributing to a total revenue increase of 6%[2] - Total revenues for the second quarter of fiscal 2025 were $983 thousand, compared to $930 thousand for the same period in fiscal 2024[9] - Total revenues for the three months ended March 31, 2025, were $983,374, representing an increase from $929,631 in the same period of 2024, a growth of approximately 5.5%[23] - Product revenues increased to $548,638 for the three months ended March 31, 2025, compared to $393,125 in the prior year, reflecting a growth of 39.6%[23] Loss and Expenses - Operating loss for the second quarter was $3.5 million, slightly improved from a loss of $3.6 million in the prior year[9] - Net loss for the quarter was $3.3 million, an improvement from a net loss of $4.5 million in the second quarter of fiscal 2024[9] - The net loss attributable to Applied DNA Sciences, Inc. for the three months ended March 31, 2025, was $3,304,175, a decrease from $4,470,474 in the same period of 2024, indicating an improvement of 26.1%[23] - The company reported a consolidated adjusted EBITDA loss of $3,322,004 for the three months ended March 31, 2025, compared to a loss of $3,255,840 in the same period of 2024[25] - Operating expenses for the three months ended March 31, 2025, totaled $3,832,642, slightly down from $3,913,402 in the same period of 2024, a decrease of 2.1%[23] Cash and Assets - Cash and cash equivalents as of March 31, 2025, were $6.8 million, including $1.0 million from the exercise of Series A warrants[9] - Cash and cash equivalents increased to $6,823,260 as of March 31, 2025, from $6,431,095 as of September 30, 2024, an increase of 6.1%[21] - Total current assets as of March 31, 2025, were $8,430,411, compared to $8,047,670 as of September 30, 2024, an increase of 4.8%[21] Liabilities - Total liabilities decreased to $2,811,455 as of March 31, 2025, from $3,820,955 as of September 30, 2024, a reduction of 26.4%[21] Future Outlook - Company anticipates a decline in quarterly cash burn starting in the quarter ending June 30, 2025, following strategic restructuring[6] - Management believes that industry tailwinds are accelerating, with significant planned investments in U.S. manufacturing and opportunities arising from limitations in competing technologies[5] - Expected launch of LineaPCR™ in Q4 2025 to simplify PCR-based drug discovery workflows[7] - New TR8™ PGx pharmacogenomic sub-panels introduced to lower adoption barriers for institutions and clinicians[9] Manufacturing Capacity - The validated GMP Site 1 manufacturing operations can support an annual revenue capacity between $10 million and $30 million, depending on product mix and pricing[7] Share Issuance - The company had 6,331,410 shares issued and outstanding as of March 31, 2025, compared to 206,324 shares as of September 30, 2024, indicating a significant increase in share issuance[21]

Financial Performance - Total revenues for the three months ended March 31, 2025, were $983,374, a 5.0% increase from $929,631 in the same period of 2024[12] - Product revenues increased to $548,638 for the three months ended March 31, 2025, compared to $393,125 in the prior year, representing a 39.6% growth[12] - Gross profit for the six months ended March 31, 2025, was $1,054,954, up from $526,748 in the same period of 2024, indicating a 100.4% increase[12] - Total revenues for the six months ended March 31, 2025, were $2,179,991, representing an increase of 19.7% compared to $1,820,795 for the same period in 2024[32] - The company reported a net loss of $6,004,833 for the six months ended March 31, 2025, compared to a net loss of $5,624,064 for the same period in 2024, indicating an increase in losses of approximately 6.7%[14] - The consolidated loss before provision for income taxes for the three-month period ended March 31, 2025, was $3,336,120, compared to $4,493,783 in 2024, showing a decrease of approximately 25.8%[94] Assets and Liabilities - Total current assets rose to $8,430,411 as of March 31, 2025, compared to $8,047,670 as of September 30, 2024, reflecting a 4.8% increase[11] - Total liabilities decreased to $2,811,455 as of March 31, 2025, down from $3,820,955 as of September 30, 2024, a reduction of 26.4%[11] - Total equity increased to $10,224,208 as of March 31, 2025, from $8,968,085 as of September 30, 2024, representing a 14.0% increase[11] - Cash and cash equivalents increased to $6,823,260 as of March 31, 2025, from $6,431,095 as of September 30, 2024, a growth of 6.1%[11] Operational Changes - The company completed a workforce reduction of approximately 20% in January 2025, resulting in a reduction of about 13% in annual payroll costs[15] - The company announced its exit from the DNA Tagging and Security Products and Services segment on February 13, 2025, and plans to continue servicing certain existing contracts[47] - The company is currently engaged in a strategic review of its MDx Testing Services business segment[110] Revenue Recognition - The Company recognizes revenue based on contracts with customers, satisfying performance obligations either at a point in time or over time[170] - PCR-produced linear DNA product revenues are recognized upon transferring control of goods to customers, with invoicing occurring upon shipment and collection terms averaging 30 to 60 days[172] - Revenue for authentication services is recognized when the authentication report is released to the customer[174] - Clinical laboratory testing service revenues, including COVID-19 testing, are recognized when testing results are released, with fixed monthly fee revenues recognized over time[175] - Research and development service revenues are recorded using the over-time revenue recognition model, primarily measured by the cost-to-cost method[176] Market and Growth Strategy - The company is focusing its growth strategy on the development and commercialization of Therapeutic DNA Production Services, including expanding its contract development and manufacturing operation (CDMO)[109] - The LineaDNA platform enables rapid, efficient, and large-scale production of high-fidelity DNA sequences, with production times measured in hours compared to days or weeks for traditional methods[115] - As of Q1 2025, there are 4,418 gene, cell, and RNA therapies in development, representing a substantial market opportunity for the LineaDNA platform[116] - The mRNA therapy market is growing rapidly, with over 450 mRNA therapies under development, 65% of which are in the preclinical stage[119] Stock and Compliance - A reverse stock split of one-for-fifty was executed on March 14, 2025, adjusting the number of shares and exercise prices of outstanding options and warrants accordingly[60][61] - The Company received a notification from Nasdaq on November 12, 2024, regarding non-compliance with the minimum bid price requirement of $1.00 per share, with a compliance deadline of May 12, 2025[76] - On April 7, 2025, the Company regained compliance with Nasdaq's minimum bid price requirement, with the closing bid price being at or above $1.00 from March 14, 2025, to April 4, 2025[77] Internal Controls and Reporting - A material weakness in internal control over financial reporting was identified, specifically related to fair value calculations for warrants, but does not require restatement of prior financial statements[184] - The Company is committed to remediating the identified material weakness by implementing controls to ensure accuracy in fair value calculations[185] - The Company has elected scaled disclosure requirements available to smaller reporting companies, which affects the information provided regarding market risk[181]

Applied DNA Sciences, Inc. (NASDAQ:APDN) Q1 2025 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Sanjay Hurry - Executive Director, IR & Corporate Communications Beth Jantzen - CFO James Hayward - Chairman & CEO Clay Shorrock - Chief Legal Officer & Executive Director, Business Development Judith Murrah - President & Secretary Conference Call Participants Eduardo Arce - H.C. Wainwright & Co Operator Good day, and welcome to the Applied DNA Sciences First Quarter Fiscal 2025 Financ ...